NO331207B1 - Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav - Google Patents

Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav

Info

Publication number
NO331207B1
NO331207B1 NO20004502A NO20004502A NO331207B1 NO 331207 B1 NO331207 B1 NO 331207B1 NO 20004502 A NO20004502 A NO 20004502A NO 20004502 A NO20004502 A NO 20004502A NO 331207 B1 NO331207 B1 NO 331207B1
Authority
NO
Norway
Prior art keywords
eprosartan
preparation
pharmaceutical composition
composition
solvate
Prior art date
Application number
NO20004502A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004502D0 (no
NO20004502L (no
Inventor
Gopadi M Venkatesh
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20004502D0 publication Critical patent/NO20004502D0/no
Publication of NO20004502L publication Critical patent/NO20004502L/no
Publication of NO331207B1 publication Critical patent/NO331207B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20004502A 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav NO331207B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (fr) 1998-03-11 1999-03-11 Compositions a base d'eprosartan

Publications (3)

Publication Number Publication Date
NO20004502D0 NO20004502D0 (no) 2000-09-08
NO20004502L NO20004502L (no) 2000-11-07
NO331207B1 true NO331207B1 (no) 2011-10-31

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004502A NO331207B1 (no) 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav

Country Status (21)

Country Link
EP (1) EP1061803B1 (fr)
JP (1) JP2002506010A (fr)
KR (1) KR20010041796A (fr)
CN (1) CN1299235A (fr)
AT (1) ATE508633T1 (fr)
AU (1) AU757547B2 (fr)
BR (1) BR9908691A (fr)
CA (1) CA2323363C (fr)
CY (1) CY1111738T1 (fr)
CZ (1) CZ303067B6 (fr)
DK (1) DK1061803T3 (fr)
ES (1) ES2366394T3 (fr)
HU (1) HU228574B1 (fr)
IL (1) IL138345A (fr)
NO (1) NO331207B1 (fr)
NZ (1) NZ506700A (fr)
PL (1) PL192545B1 (fr)
SI (1) SI1061803T1 (fr)
TR (1) TR200002646T2 (fr)
WO (1) WO1999045779A1 (fr)
ZA (1) ZA991922B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
WO2000004862A2 (fr) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Formulations bioameliorees comprenant de l'eprosartane dans des formes galeniques solides destinees a une administration orale
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2405895A1 (fr) * 2000-04-12 2001-10-18 Ronald Edward Steele Combinaison de composes organiques
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (fr) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Utilisation d'un agent bloquant du récepteur AT1 de l'angiotensine II, seul ou combiné avec un thiazide ou l'angiotensine II dans le traitement des accidents vasculaires cérébraux
US20060210620A1 (en) * 2003-01-21 2006-09-21 Kumra Pannanchukunnath M Co-precipitated amorphous losartan and dosage forms comprising the same
EP3045174A1 (fr) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Médicament pour la prévention et le traitement de l'artériosclérose et de l'hypertension
CN1972679B (zh) * 2004-06-23 2010-07-28 索尔瓦药物有限公司 包括nep-抑制剂、内源性内皮缩血管肽产生系统抑制剂和at1受体拮抗剂的药物组合物
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (fr) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Particules micronisees sensiblement pures de telmisartan et compositions pharmaceutiques renfermant celles-ci
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
WO2009013760A2 (fr) * 2007-07-25 2009-01-29 Hetero Drugs Limited Particules cristallines de mésylate d'éprosartan et procédé de préparation d'éprosartan pur
EP2108365A1 (fr) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Formule pharmaceutique à dosage simple comportant du mesylate d'eprosartan
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE239723T1 (de) * 1996-03-29 2003-05-15 Smithkline Beecham Corp Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung
NZ502644A (en) * 1997-08-06 2002-03-01 Smithkline Beecham Corp Eprosartan arginyl charge-neutralization-complex useful for treating diseases where blockade of the angiotensin II receptor is indicated

Also Published As

Publication number Publication date
IL138345A (en) 2004-12-15
ATE508633T1 (de) 2011-05-15
KR20010041796A (ko) 2001-05-25
CY1111738T1 (el) 2015-10-07
EP1061803A1 (fr) 2000-12-27
CN1299235A (zh) 2001-06-13
TR200002646T2 (tr) 2001-01-22
JP2002506010A (ja) 2002-02-26
ZA991922B (en) 1999-09-13
NO20004502D0 (no) 2000-09-08
PL192545B1 (pl) 2006-11-30
CZ303067B6 (cs) 2012-03-21
HUP0101243A3 (en) 2005-09-28
EP1061803B1 (fr) 2011-05-11
CA2323363C (fr) 2008-09-30
AU757547B2 (en) 2003-02-27
SI1061803T1 (sl) 2011-09-30
AU2890999A (en) 1999-09-27
NO20004502L (no) 2000-11-07
HU228574B1 (en) 2013-04-29
HUP0101243A1 (hu) 2002-05-29
PL343411A1 (en) 2001-08-13
BR9908691A (pt) 2000-12-26
ES2366394T3 (es) 2011-10-19
CA2323363A1 (fr) 1999-09-16
IL138345A0 (en) 2001-10-31
DK1061803T3 (da) 2011-08-29
NZ506700A (en) 2003-03-28
EP1061803A4 (fr) 2007-12-26
WO1999045779A1 (fr) 1999-09-16
CZ20003288A3 (cs) 2001-03-14

Similar Documents

Publication Publication Date Title
NO331207B1 (no) Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav
WO2000004862A3 (fr) Formulations bioameliorees comprenant de l'eprosartane dans des formes galeniques solides destinees a une administration orale
MY127793A (en) Novel form of s-omeprazole.
NO20003530D0 (no) Vedvarende frigivelsessammensetning, metode for dens produksjon og anvendelse derav
WO2002044156A3 (fr) Composes chimiques
DE60034728D1 (de) Verfahren zur Massenanfertigung von beschichteten, elektrochirurgischen Elektroden
HK1035183A1 (en) New hydroxyindoles, their use as phosphodiesterase4 inhibitors and method for producing same.
RO118870B1 (ro) Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
TR199800608A3 (tr) Propanolamin türevleri, bunlarin üretim usulü.
WO2006052461A3 (fr) Nouvelles formulations d'eprosartan presentant une biodisponibilite amelioree
NO20043371L (no) Kortikotropinfrigjorendefaktorreseptor-2 agonister
DE50012584D1 (de) Keramikhaltiges dispergat, verfahren zu dessen herstellung und verwendung des dispergates in dickschichtpasten
DE60141654D1 (de) Verfahren für die herstellung von heterorylaminderivaten
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
MY118704A (en) Process for preparation of eprosartan
ZA200005540B (en) New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same.
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
GB2384779B (en) Method for the production of tagged proteins
WO2000073333A3 (fr) Ligand pour cd7 et procedes d'utilisation
DE69905772D1 (de) Verfahren zur rückgewinnung von 3,4-epoxy-1-buten
YU58702A (sh) Postupak za proizvodnju 5-arilnikotinaldehida
FR2842516B1 (fr) Composition d'ensimage pour verranne, procede utilisant cette composition et produits resultants
DE60130385D1 (de) Verfahren zur Erhöhung der Eierproduktion und Verfestigung von Eierschalen bei Geflügel
WO2000041472A3 (fr) Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees